Followers | 300 |
Posts | 33564 |
Boards Moderated | 2 |
Alias Born | 08/07/2004 |
![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Thursday, January 24, 2013 7:57:30 PM
I guess my point was more along the lines of don't attach too much importance to it beyond that it IS a positive.
and that was the significance I attached to it...its a huge positive IMO.
Saving 24 months is significant dollar wise to the company and certainly to folks that need this treatment. I dont think Church was BSn me when he said it was the FDAs mindset there is urgency to get treatment for HCC out there ASAP, hence the move straight to P3. Must have been something they saw they liked a lot from P1.
Again I will say 33% was the number they agreed upon satisfying the FDA and it was also a number the company was comfortable with. I think the trial was designed by some of the best in the world, not to be a coin toss on the chances for success. In view of this JMO, 33% is going to be cleared with air to spare.
Results please
Cannabix Technologies and Omega Laboratories Inc. Provide Positive Developments on Marijuana Breathalyzer Testing • BLO • Jul 11, 2024 8:21 AM
ECGI Holdings Enhances Board with Artificial Intelligence (AI) Expert Ahead of Allon Apparel Launch • ECGI • Jul 10, 2024 8:30 AM
Avant Technologies to Meet Unmet Needs in AI Industry While Addressing Sustainability Concerns • AVAI • Jul 10, 2024 8:00 AM
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM